|
1
|
Shiraha H, Yamamoto K and Namba M: Human
hepatocyte carcinogenesis (Review). Int J Oncol. 42:1133–1138.
2013.PubMed/NCBI
|
|
2
|
Finn RS: Emerging targeted strategies in
advanced hepatocellular carcinoma. Semin Liver Dis. 33(Suppl 1):
S11–S19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Whittaker S, Marais R and Zhu AX: The role
of signaling pathways in the development and treatment of
hepatocellular carcinoma. Oncogene. 29:4989–5005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carr BI: Some new approaches to the
management of hepatocellular carcinoma. Semin Oncol. 39:369–373.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamed O, Kimchi ET, Sehmbey M, Gusani NJ,
Kaifi JT and Staveley-O’Carroll K: Impact of genetic targets on
cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 779:67–90.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marrero JA: Multidisciplinary management
of hepatocellular carcinoma: where are we today? Semin Liver Dis.
33(Suppl 1): S3–S10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alves RC, Alves D, Guz B, Matos C, Viana
M, Harriz M, Terrabuio D, Kondo M, Gampel O and Polletti P:
Advanced hepatocellular carcinoma. Review of targeted molecular
drugs. Ann Hepatol. 10:21–27. 2011.PubMed/NCBI
|
|
8
|
Herszényi L and Tulassay Z: Epidemiology
of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci.
14:249–258. 2010.PubMed/NCBI
|
|
9
|
Hussain SA, Ferry DR, El-Gazzaz G, Mirza
DF, James ND, McMaster P and Kerr DJ: Hepatocellular carcinoma. Ann
Oncol. 12:161–172. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka M, Katayama F, Kato H, Tanaka H,
Wang J, Qiao YL and Inoue M: Hepatitis B and C virus infection and
hepatocellular carcinoma in China: a review of epidemiology and
control measures. J Epidemiol. 21:401–416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Serag HB: Hepatocellular carcinoma: an
epidemiologic view. J Clin Gastroenterol. 35(5 Suppl 2): S72–S78.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai EC and Lau WY: The continuing
challenge of hepatic cancer in Asia. Surgeon. 3:210–215. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuen MF, Hou JL and Chutaputti A; Asia
Pacific Working Party on Prevention of Hepatocellular Carcinoma.
Hepatocellular carcinoma in the Asia pacific region. J
Gastroenterol Hepatol. 24:346–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grossman EJ and Millis JM: Liver
transplantation for non-hepatocellular carcinoma malignancy:
Indications, limitations, and analysis of the current literature.
Liver Transpl. 16:930–942. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaido T, Mori A, Ogura Y, Hata K,
Yoshizawa A, Iida T and Uemoto S: Living donor liver
transplantation for recurrent hepatocellular carcinoma after liver
resection. Surgery. 151:55–60. 2012. View Article : Google Scholar
|
|
16
|
Ambros V, Bartel B, Bartel DP, Burge CB,
Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S,
Marshall M, Matzke M, Ruvkun G and Tuschl T: A uniform system for
microRNA annotation. RNA. 9:277–279. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schetter AJ and Harris CC: Alterations of
microRNAs contribute to colon carcinogenesis. Semin Oncol.
38:734–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Zhang L and Hao Q: Candidate
microRNA biomarkers in human epithelial ovarian cancer: systematic
review profiling studies and experimental validation. Cancer Cell
Int. 13:862013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng B, Wang R and Chen LB: Review of
miR-200b and cancer chemosensitivity. Biomed Pharmacother.
66:397–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao J, Zhou E, Wang Y, Xu F, Zhang D and
Zhong D: microRNA-200a inhibits cell proliferation by targeting
mitochondrial transcription factor A in breast cancer. DNA Cell
Biol. 33:291–300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cong N, Du P, Zhang A, Shen F, Su J, Pu P,
Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a
promotes EMT and tumor growth through the wnt/β-catenin pathway by
targeting the E-cadherin repressors ZEB1/ZEB2 in gastric
adenocarcinoma. Oncol Rep. 29:1579–1587. 2013.PubMed/NCBI
|
|
23
|
Kobayashi M, Salomon C, Tapia J, Illanes
SE, Mitchell MD and Rice GE: Ovarian cancer cell invasiveness is
associated with discordant exosomal sequestration of Let-7 miRNA
and miR-200. J Transl Med. 12:42014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lam SS, Mak AS, Yam JW, Cheung AN, Ngan HY
and Wong AS: Targeting estrogen-related receptor alpha inhibits
epithelial-to-mesenchymal transition and stem cell properties of
ovarian cancer cells. Mol Ther. 22:743–751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu L, Zou J, Wang Q, Yin FQ, Zhang W and
Li L: Novel microRNAs expression of patients with chemotherapy
drug-resistant and chemotherapy-sensitive epithelial ovarian
cancer. Tumour Biol. 35:7713–7717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S,
Wang Y, Guo Q, Wang L, Huang Y, Zhu M and Wang Z: MiR-200a inhibits
epithelial-mesenchymal transition of pancreatic cancer stem cell.
BMC Cancer. 14:852014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Q, Zou X, Zhang T, Shen J, Yin Y and
Xiang J: The role of miR-200a in vasculogenic mimicry and its
clinical significance in ovarian cancer. Gynecol Oncol.
132:730–738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banyard J, Chung I, Wilson AM, Vetter G,
Le Béchec A, Bielenberg DR and Zetter BR: Regulation of epithelial
plasticity by miR-424 and miR-200 in a new prostate cancer
metastasis model. Sci Rep. 3:31512013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao Q, Lu K, Dai S, Hu Y and Fan W:
Clinicopathological and prognostic implications of the miR-200
family in patients with epithelial ovarian cancer. Int J Clin Exp
Pathol. 7:2392–2401. 2014.PubMed/NCBI
|
|
30
|
Kolesnikoff N, Attema JL, Roslan S, Bert
AG, Schwarz QP, Gregory PA and Goodall GJ: Specificity protein 1
(Sp1) maintains basal epithelial expression of the miR-200 family:
implications for epithelial-mesenchymal transition. J Biol Chem.
289:11194–11205. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koutsaki M, Spandidos DA and Zaravinos A:
Epithelial-mesenchymal transition-associated miRNAs in ovarian
carcinoma, with highlight on the miR-200 family: prognostic value
and prospective role in ovarian cancer therapeutics. Cancer Lett.
351:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song F1, Yang D, Liu B, Guo Y, Zheng H, Li
L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X
and Chen K: Integrated microRNA network analyses identify a
poor-prognosis subtype of gastric cancer characterized by the
miR-200 family. Clin Cancer Res. 20:878–889. 2014. View Article : Google Scholar
|
|
33
|
Truong HH, Xiong J, Ghotra VP, Nirmala E,
Haazen L, Le Dévédec SE, Balcioğlu HE, He S, Snaar-Jagalska BE,
Vreugdenhil E, Meerman JH, van de Water B and Danen EH: β1 integrin
inhibition elicits a prometastatic switch through the
TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative
breast cancer. Sci Signal. 7:ra152014. View Article : Google Scholar
|
|
34
|
Wang CH, Chen CL, More SV, Hsiao PW, Hung
WC and Li WS: The tetraindole SK228 reverses the
epithelial-to-mesenchymal transition of breast cancer cells by
up-regulating members of the miR-200 family. PLoS One.
9:e1010882014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang CM, Liu R, Wang L, Nascimento L,
Brennan VC and Yang WH: SUMOylation of FOXM1B alters its
transcriptional activity on regulation of miR-200 family and JNK1
in MCF7 human breast cancer cells. Int J Mol Sci. 15:10233–10251.
2014. View Article : Google Scholar : PubMed/NCBI
|
